Effective delivery of arsenic trioxide to HPV-positive cervical cancer cells using optimised liposomes: a size and charge study
Article
Akhtar, A., Wang, S., Ghali, L., Bell, C. and Wen, S. 2018. Effective delivery of arsenic trioxide to HPV-positive cervical cancer cells using optimised liposomes: a size and charge study. International Journal of Molecular Sciences. 19 (4), pp. 1-14. https://doi.org/10.3390/ijms19041081
Type | Article |
---|---|
Title | Effective delivery of arsenic trioxide to HPV-positive cervical cancer cells using optimised liposomes: a size and charge study |
Authors | Akhtar, A., Wang, S., Ghali, L., Bell, C. and Wen, S. |
Abstract | Despite the success of arsenic trioxide (ATO) in treating haematological malignancies, its potential to treat solid tumours has not been fully exploited, owing to its dose-limiting toxicity and poor pharmacokinetics. In order to overcome this hurdle, liposomal encapsulation of the drug with different surface charges (neutral, negative, and positive) and sizes (100, 200 and 400 nm) were synthesised and tested on human papilloma virus (HPV)-positive HeLa and HPV-negative HT-3 cervical cancer cell lines. Two epithelial cell lines-human keratinocytes (HK) and human colon cells (CRL-1790)-were used as controls. The synthesised liposomes were tested for their physico-chemical characteristics, drug loading efficiency, and toxicity on the studied cell lines. Neutral liposomes of 100 nm in size were the chosen formulation for delivering ATO into the studied cells, as they showed the least intrinsic cytotoxicity and the highest loading efficiency. The findings demonstrated that the optimised formulation of liposomes was an effective drug delivery method for HPV-infected cervical cancer cells. Furthermore, the toxicity vs. uptake ratio was highest for HeLa cells, while a reduced or minimal toxic effect was observed for non-HPV-infected cervical cancer cells and control cells. These findings may provide a promising therapeutic strategy for effectively managing cervical cancers. |
Keywords | arsenic trioxide (ATO); cervical cancer; drug delivery; human papilloma virus (HPV); liposome |
Publisher | MDPI AG |
Journal | International Journal of Molecular Sciences |
ISSN | 1661-6596 |
Electronic | 1422-0067 |
Publication dates | |
Online | 04 Apr 2018 |
30 Apr 2018 | |
Publication process dates | |
Deposited | 03 Jul 2018 |
Accepted | 03 Apr 2018 |
Output status | Published |
Publisher's version | License |
Copyright Statement | © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
Additional information | This article belongs to the Special Issue Nanotechnology in Drug Delivery |
Digital Object Identifier (DOI) | https://doi.org/10.3390/ijms19041081 |
Web of Science identifier | WOS:000434978700160 |
Language | English |
https://repository.mdx.ac.uk/item/87v34
Download files
46
total views8
total downloads0
views this month0
downloads this month